Holen Sie sich die Stockscreener-App
0.451
2.00%
-0.0092
Handel nachbörslich:
.43
-0.021
-4.66%
Schlusskurs vom Vortag:
$0.4602
Offen:
$0.46
24-Stunden-Volumen:
53,095
Relative Volume:
1.29
Marktkapitalisierung:
$10.52M
Einnahmen:
$2.82M
Nettoeinkommen (Verlust:
$-14.20M
KGV:
-0.5306
EPS:
-0.85
Netto-Cashflow:
$-15.13M
1W Leistung:
+4.76%
1M Leistung:
-8.15%
6M Leistung:
-13.95%
1J Leistung:
-50.78%
1-Tages-Spanne:
$0.45
$0.479
1-Wochen-Bereich:
$0.43
$0.48
52-Wochen-Spanne:
$0.43
$1.19
Talphera Inc Stock (TLPH) Company Profile
Firmenname
Talphera Inc
Sektor
Telefon
650-216-3500
Adresse
1850 GATEWAY DRIVE, SAN MATEO
Vergleichen Sie TLPH mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TLPH
Talphera Inc
|
0.451 | 10.52M | 2.82M | -14.20M | -15.13M | -0.85 |
|
RGC
Regencell Bioscience Holdings Ltd
|
14.60 | 303.95B | 0 | -5.87M | -767.30K | -0.45 |
|
ZTS
Zoetis Inc
|
159.19 | 74.39B | 9.29B | 2.52B | 2.28B | 5.57 |
|
HLN
Haleon Plc Adr
|
10.35 | 48.97B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.37 | 47.39B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.64 | 20.17B | 16.54B | -1.64B | 749.00M | -1.45 |
Talphera Inc Stock (TLPH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-28 | Eingeleitet | Rodman & Renshaw | Buy |
| 2020-07-20 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2019-11-11 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2019-08-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2019-07-10 | Fortgesetzt | Credit Suisse | Outperform |
| 2019-04-24 | Fortgesetzt | B. Riley FBR | Buy |
| 2019-02-15 | Eingeleitet | Credit Suisse | Outperform |
| 2018-10-23 | Eingeleitet | B. Riley FBR | Buy |
| 2017-10-13 | Herabstufung | Jefferies | Buy → Hold |
| 2017-10-13 | Bestätigt | RBC Capital Mkts | Outperform |
| 2017-07-14 | Fortgesetzt | Jefferies | Buy |
| 2016-09-15 | Bestätigt | ROTH Capital | Buy |
| 2016-08-05 | Herabstufung | Stifel | Buy → Hold |
| 2015-10-30 | Hochstufung | Jefferies | Hold → Buy |
| 2015-10-05 | Bestätigt | ROTH Capital | Buy |
| 2015-09-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2015-07-10 | Fortgesetzt | ROTH Capital | Buy |
| 2015-05-06 | Bestätigt | Mizuho | Neutral |
| 2015-05-05 | Bestätigt | RBC Capital Mkts | Outperform |
| 2015-03-10 | Bestätigt | RBC Capital Mkts | Outperform |
| 2015-03-09 | Herabstufung | Mizuho | Buy → Neutral |
Alle ansehen
Talphera Inc Aktie (TLPH) Neueste Nachrichten
Talphera, Inc. (NASDAQ:TLPH) Q1 2025 Earnings Call Transcript - MSN
talphera receives extension to meet nasdaq listing requirements - Investing.com India
talphera receives extension to meet nasdaq listing requirements By Investing.com - Investing.com South Africa
Talphera Granted Extension for Nasdaq Compliance - TipRanks
Financial Review: Talphera (NASDAQ:TLPH) & Alterity Therapeutics (NASDAQ:ATHE) - Defense World
Talphera’s Strategic Advancements and Financial Stability Reinforce Buy Rating - TipRanks
Talphera outlines accelerated NEPHRO CRRT study timeline with completion targeted by end of 2025, supported by new site activations and $14.8M financing - MSN
Talphera, Inc. Earnings Call: Strategic Adjustments and Financial Progress - TipRanks
TLPH Prepares to Finalize NEPHRO CRRT Registration Trial | TLPH Stock News - GuruFocus
Talphera: Q1 Earnings Snapshot - Greenwich Time
Talphera Inc (TLPH) Q1 2025 Earnings Call Highlights: Strategic Cost Reductions and FDA ... - Yahoo Finance
Talphera, Inc. Reports Q1 2025 Financial Results - TipRanks
Talphera Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Earnings call transcript: Talphera Inc. outlines strategic shifts in Q1 2025 - Investing.com Nigeria
TLPH Reports Strong Q1 Revenue with Promising Study Progress | T - GuruFocus
Talphera Inc Reports Q1 2025 EPS Loss of $0.10, Beating Estimates; Revenue Details Unavailable - GuruFocus
TALPHERA, INC. SEC 10-Q Report - TradingView
TLPH Reports Strong Q1 Revenue with Promising Study Progress | TLPH Stock News - GuruFocus
Talphera Announces First Quarter 2025 Financial Results and Prov - GuruFocus
Talphera Cuts Net Loss 32%, Secures FDA Approval for Streamlined Clinical Trial Design - Stock Titan
Talphera Announces First Quarter 2025 Financial Results and Provides Corporate Update | TLPH Stock News - GuruFocus
Talphera reports Q1 EPS (10c), consensus (14c) - TipRanks
Talphera Announces First Quarter 2025 Financial Results and Provides Corporate Update - PR Newswire
Talphera to Host First Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, May 14, 2025 - Citizen Tribune
Talphera to Host First Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, May 14, 2025 | TLPH Stock News - GuruFocus
All You Need to Know About Talphera (TLPH) Rating Upgrade to Strong Buy - Yahoo Finance
HC Wainwright Predicts Talphera’s Q1 Earnings (NASDAQ:TLPH) - Defense World
Talphera (TLPH) Upgraded to Buy: What Does It Mean for the Stock? - MSN
HC Wainwright Estimates Talphera FY2029 Earnings - Defense World
Talphera CEO Makes Bold Move with Major Stock Purchase! - TipRanks
Talphera CEO Vincent Angotti buys $124,999 in common stock By Investing.com - Investing.com Canada
Talphera CEO Vincent Angotti buys $124,999 in common stock - Investing.com
Talphera (NASDAQ:TLPH) Given Buy Rating at HC Wainwright - Defense World
Talphera, Inc. Earnings Call: Progress Amid Challenges - TipRanks
H.C. Wainwright maintains Buy on Talphera stock, $6 target By Investing.com - Investing.com Canada
Strategic Advancements and FDA Agreement Propel Talphera’s Positive Outlook with Buy Rating - TipRanks
H.C. Wainwright maintains Buy on Talphera stock, $6 target - Investing.com India
Talphera: Q4 Earnings Snapshot - CT Insider
Talphera Inc (TLPH) Q4 2024 Earnings Call Highlights: Strategic Moves and Financial Insights - Yahoo Finance
Talphera Reports 2024 Financial Results and Study Update - TipRanks
Talphera outlines 2025 timeline for NEPHRO CRRT study completion and FDA approval of Niyad - MSN
Earnings call transcript: Talphera Inc Q4 2024 shows strategic focus - Investing.com India
FDA approves Talphera’s reduced NEPHRO CRRT study size By Investing.com - Investing.com South Africa
Earnings call transcript: Talphera Inc Q4 2024 shows strategic focus By Investing.com - Investing.com UK
TLPH stock touches 52-week low at $0.5 amid market challenges By Investing.com - Investing.com South Africa
TALPHERA, INC. SEC 10-K Report - TradingView
Finanzdaten der Talphera Inc-Aktie (TLPH)
Umsatz
Nettogewinn
Free Cashflow
ENV
Talphera Inc-Aktie (TLPH) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Angotti Vincent J. | CHIEF EXECUTIVE OFFICER |
Dec 05 '24 |
Buy |
0.64 |
5,000 |
3,200 |
208,066 |
| ASADORIAN RAFFI | Chief Financial Officer |
Dec 02 '24 |
Sale |
0.77 |
155 |
119 |
37,578 |
| Angotti Vincent J. | CHIEF EXECUTIVE OFFICER |
Nov 27 '24 |
Buy |
0.73 |
5,000 |
3,650 |
203,066 |
1.05%
0.60%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):